These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7977011)

  • 41. [Lipid-lowering therapy in patients with coronary disease: proportion of patients requiring treatment according to recommendations of the Swiss Society of Cardiology].
    Muntwyler J; Amann FW; Gutzwiller F; Follath F
    Schweiz Med Wochenschr; 1999 Dec; 129(50):1959-63. PubMed ID: 10637948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic prevention of coronary artery disease. What do clinical trials show?
    Milani RV; Lavie CJ
    Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statin trials and goals of cholesterol-lowering therapy.
    Grundy SM
    Circulation; 1998 Apr; 97(15):1436-9. PubMed ID: 9576422
    [No Abstract]   [Full Text] [Related]  

  • 45. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Will serum lipid lowering treatment reduce the incidence of coronary heart disease?
    Vessby B; Lithell H; Boberg J
    Artery; 1981; 9(5):372-81. PubMed ID: 7032466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials.
    Anderson JW; Allgood LD; Lawrence A; Altringer LA; Jerdack GR; Hengehold DA; Morel JG
    Am J Clin Nutr; 2000 Feb; 71(2):472-9. PubMed ID: 10648260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Making practical sense of clinical trial data in decreasing cardiovascular risk.
    Castelli WP
    Am J Cardiol; 2001 Aug; 88(4A):16F-20F. PubMed ID: 11520482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract]   [Full Text] [Related]  

  • 52. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.
    Buchwald H; Campos CT; Boen JR; Nguyen P; Williams SE; Lau J; Chalmers TC
    Ann Surg; 1996 Oct; 224(4):486-98; discussion 498-500. PubMed ID: 8857853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
    Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes.
    Peters SA; den Ruijter HM; Bots ML
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):253-63. PubMed ID: 21657803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
    Bays H
    Am J Cardiol; 2002 Nov; 90(10B):30K-43K. PubMed ID: 12467938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug treatment of hyperlipidemia in women.
    Walsh JM; Pignone M
    JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies.
    Tyroler HA
    Circulation; 1987 Sep; 76(3):515-22. PubMed ID: 3304704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
    Lan J; Zhao Y; Dong F; Yan Z; Zheng W; Fan J; Sun G
    J Ethnopharmacol; 2015 Feb; 161():69-81. PubMed ID: 25498346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The role of lipid metabolism in the prevention of coronary heart disease].
    Mathes P; Thiery J
    Z Kardiol; 2005; 94 Suppl 3():III/43-55. PubMed ID: 16258792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.